Marker Therapeutics, Inc.

Monthly Archives: August 2019

Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs

Marker Therapeutics today announced the appointment of Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs, effective August 15.
Read More

Marker Therapeutics Reports Second Quarter 2019 Operating and Financial Results

Marker Therapeutics today provided a corporate update and reported financial results for the second quarter ended June 30, 2019.
Read More

Marker Therapeutics Appoints Steve Elms to its Board of Directors

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Steve Elms, to its Board of Directors, effective August 6.
Read More